SCHEMBL3938575

SCHEMBL3938575

COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1cc(C(=O)N(C)CCN(C)C)n(C)c1)c1ccc2c(c1)OCCO2

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 3/20 0.35
TP53 P04637 2/20 0.35
ALOX15 P16050 1/20 0.35
KDM4E B2RXH2 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
MAPT P10636 2/20 0.34
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
NPC1 O15118 1/20 0.33
CASP3 P42574 1/20 0.33
RAB9A P51151 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
TRPV1 Q8NER1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3938578 1.00 RXFP1 (0.35) RXFP1TP53ALOX15KDM4EMEN1
SCHEMBL3933021 0.96 RAB9A (0.38) RXFP1KDM4EMEN1KMT2AMAPT
SCHEMBL3933019 0.96 RAB9A (0.38) RXFP1KDM4EMEN1KMT2AMAPT
SCHEMBL3938186 0.91 POLB (0.39) ALOX15KDM4EMEN1KMT2AMAPT
SCHEMBL5856628 0.91 POLB (0.39) ALOX15KDM4EMEN1KMT2AMAPT
SCHEMBL3943784 0.89 MAPT (0.41) RXFP1KDM4EMEN1KMT2AMAPT
SCHEMBL3943782 0.89 MAPT (0.41) RXFP1KDM4EMEN1KMT2AMAPT
SCHEMBL3846076 0.88 PRKCA (0.36) TP53KMT2AALDH1A1POLB
SCHEMBL5858144 0.87 UTS2R (0.38) TP53MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL3942426 0.87 UTS2R (0.38) TP53MEN1KMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551830-B1 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA (DE) 2009-04-08 EP disclosed
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 RXFP1 1750/4885TP53 398/4885ALOX15 2378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.